Rebus Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 21, 2022 at 10:13 pm
Share
Rebus Holdings, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net income was USD 0.316 million compared to USD 6.13 million a year ago. Basic earnings per share from continuing operations was USD 0.01.
For the nine months, net loss was USD 1.66 million compared to net income of USD 2.65 million a year ago. Basic loss per share from continuing operations was USD 0.05. Diluted loss per share from continuing operations was USD 0.05.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
REBUS HOLDINGS, INC. 
